Menagen

What Menagen does

Menagen Pharmaceutical Industries is a privately held Omani pharmaceutical manufacturer headquartered in Muscat and operating as a subsidiary of Taiba Group. The company develops, manufactures, and commercializes branded pharmaceutical products across three therapeutic areas: Specialty Care (diabetes, dyslipidemia, hyperphosphatemia, heart failure), Cardio/Hematology (anemia management, chemotherapy-induced neutropenia), and Rare Diseases (Hereditary Tyrosinemia Type I, Cystic Fibrosis, Hereditary Angioedema, Pulmonary Arterial Hypertension). Its branded portfolio includes products such as Ezirosy, Renagen, Nab-Paclitaxel, Dapaflozin, Menaxaparin, Darbegen, Ryzeuta, Ivacaf, and Icatigen.

The company's core technology is a 12,000 square meter pharmaceutical manufacturing plant in Rusayl Industrial Area, Muscat, constructed to U.S. FDA and European Medicines Agency (EMA) standards with an investment exceeding OMR 20 million. The facility is positioned as the first in the Middle East dedicated to rare disease and cancer treatment manufacturing. Menagen also operates a Development and Innovation Center established in partnership with Sultan Qaboos University's Centre for Medical Research, focused on drug discovery and development preliminary studies.

Menagen's commercial model is B2B pharmaceutical sales through direct relationships with healthcare providers, hospitals, clinics, and government health ministries. Pricing is not publicly disclosed, and the revenue stream is primarily one-time product sales of specialty and rare disease medications. The company sells principally to the Oman Ministry of Health and is actively pursuing export relationships across the MENA region, evidenced by government-level bilateral engagements with Tunisia. Distribution is direct, with no third-party logistics or reseller channels disclosed. Marketing is conducted through organic social media (LinkedIn, Instagram, Facebook, X), blog content, and earned media coverage of government visits and facility launches.

Name

Menagen

Legal name

Menagen Pharmaceutical Industries

Website

https://menagentx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

101–250 employees

Short description

Menagen Pharmaceutical Industries is an Omani pharmaceutical manufacturer operating a 12,000 sq meter FDA/EMA-compliant facility in Muscat, producing branded specialty, cardio/hematology, and rare disease medications for healthcare providers and government health ministries across the MENA region.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Pharmaceutical manufacturing
• Rare disease treatments
• Oncology medications
• Specialty care drugs
• Cardiovascular pharmaceuticals

Headquarters

HQ city

Muscat

HQ country

Oman

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and selling proprietary pharmaceutical medications for rare diseases, cancer treatments, cardiovascular conditions, and specialty care. Revenue generated through product sales to healthcare providers, hospitals, clinics, and government health institutions.
2. Specialty Medications: High-value specialty pharmaceutical products including treatments for rare diseases, cancer therapies, and complex chronic conditions requiring specialized manufacturing capabilities.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Menagen is a pharmaceutical manufacturer that develops, produces, and supplies branded medications for rare diseases, cancer treatments, cardiovascular and hematological conditions, and specialty care therapeutics. Operating from a 12,000 sqm manufacturing facility in Muscat, Oman built to FDA and EMA standards, the company produces branded formulations such as Nitisinone Menagen, Ivacaf, Icatigen, Nab-Paclitaxel, Dapaflozin, Ezirosy, Renagen, and Ryzeuta, distributing them to hospitals, clinics, pharmacies, and government health ministries across the MENA region.

Product overview

Menagen is a pharmaceutical company offering a portfolio of branded medications across three therapeutic areas: Specialty Care (diabetes, dyslipidemia, hyperphosphatemia, heart failure), Cardio/Hematology (anemia management, chemotherapy support), and Rare Diseases (Pulmonary Arterial Hypertension, Hereditary Tyrosinemia Type I, Cystic Fibrosis, Hereditary Angioedema). The company's product portfolio includes branded formulations such as Ezirosy, Renagen, Nab-Paclitaxel, Dapaflozin, Menaxaparin, Darbegen, Ryzeuta, Ivacaf, Icatigen, and Nitisinone Menagen. Menagen operates a state-of-the-art pharmaceutical manufacturing facility in Rusayl Industrial Area, Muscat, Oman, providing integrated medication development, manufacturing, research and development, and quality assurance services.

Differentiator

Problem solved

Functional benefit

Brands

• Ezirosy®: Ezetimibe 10 mg / Rosuvastatin 20 mg - Supporting cholesterol management in dyslipidemia.
• Renagen®
• Nab-Paclitaxel®
• Dapaflozin®
• Menaxaparin®
• Darbegen®
• Ryzeuta®
• Nitisinone Menagen®
• Ivacaf®
• Icatigen®
• Ambrisentan/tadalafil

Products and services

• Nitisinone Menagen

Quantifiable outcome

• First pharmaceutical plant in Middle East dedicated to rare diseases and cancer treatments
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Sultan Qaboos University Centre for Medical ResearchcoreStrategic or Co-development Partner · 11 February 2025Partnership to establish a development and innovation center at Menagen's facility, the first of its kind in the Middle East. The center aims to facilitate preliminary studies and research in drug discovery and development, advancing Oman's capabilities in pharmaceutical innovation.
• Taiba GroupcoreOthersParent company relationship with Taiba Group. Menagen Pharmaceutical Industries is headquartered at Taiba Group Headquarters in Rusayl Industrial Area, Muscat.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical manufacturer with a strong branded and generic portfolio across MENA and the US. Most directly comparable MENA-listed pharma peer to Menagen in scale, business model, and regional focus.
• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer producing branded generics across multiple therapeutic areas for the MENA region. Comparable regional manufacturer with similar B2B distribution to government health ministries and hospitals.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi-listed pharmaceutical manufacturer serving the GCC and broader MENA region. Direct comparable in branded generics manufacturing, regulatory positioning, and government-channel distribution.
• Tabuk Pharmaceuticals: Saudi-based pharmaceutical company focused on branded generics across cardiovascular, CNS, and specialty therapy areas. Closely comparable regional manufacturer targeting MENA institutional customers.
• EIPICO (Egyptian International Pharmaceutical Industries): One of the largest pharmaceutical manufacturers in the MENA region, based in Egypt. Comparable in scale, branded-generic portfolio breadth, and regional distribution model to Menagen.
• Pharma International (Jordan): Jordan-based pharmaceutical manufacturer part of the Pharmacare group, with branded generics across MENA. Comparable as a regional manufacturer with multi-therapy-area portfolio and B2B distribution.

Broad incumbents

• Cipla: Major Indian multinational pharmaceutical company with a significant branded generics portfolio in MENA, including oncology, respiratory, and specialty care. Comparable in product categories and emerging-market distribution model.
• Sanofi: Global pharmaceutical major with a strong rare disease franchise via Genzyme (e.g., rare disease therapies). Comparable as a broader player operating in rare diseases and specialty care that Menagen is targeting.
• Roche: Global pharmaceutical leader with dominant oncology and rare disease franchises. Comparable as the dominant incumbent whose branded therapies (e.g., paclitaxel-class) compete with Menagen's oncology portfolio.

Emerging players

• Vertex Pharmaceuticals: Specialty pharmaceutical company focused on cystic fibrosis (where Menagen markets Ivacaf/Ivacaftor). Comparable as a rare-disease focused innovator that defines the competitive benchmark for Menagen's rare disease portfolio.

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Menagentx
• Facebookfacebook.com/menagen.om
• LinkedInlinkedin.com/company/menagen
• Instagraminstagram.com/menagen.om/?hl=en

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Menagen